You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Salix Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Salix Pharms
International Patents:326
US Patents:40
Tradenames:9
Ingredients:8
NDAs:9

Drugs and US Patents for Salix Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 AP RX Yes Yes 9,669,096 ⤷  Sign Up Y ⤷  Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 7,906,542 ⤷  Sign Up Y Y ⤷  Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 7,045,620 ⤷  Sign Up Y ⤷  Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 9,629,828 ⤷  Sign Up ⤷  Sign Up
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes 10,376,584 ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Salix Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 7,045,620 ⤷  Sign Up
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 6,559,158 ⤷  Sign Up
Salix Pharms VISICOL sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate TABLET;ORAL 021097-001 Sep 21, 2000 5,616,346 ⤷  Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 8,158,781 ⤷  Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 8,158,644 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SALIX PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 12 mg/0.6 mL ➤ Subscribe 2015-07-22
➤ Subscribe Tablets 150 mg ➤ Subscribe 2016-09-06
➤ Subscribe Tablets 1.102 g and 0.398 g ➤ Subscribe 2008-04-09
➤ Subscribe Tablets 200 mg ➤ Subscribe 2019-01-28
➤ Subscribe For Oral Solution 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch ➤ Subscribe 2007-11-27
➤ Subscribe Injection 8 mg/0.4 mL ➤ Subscribe 2015-09-08
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-08-24
➤ Subscribe Tablets 550 mg ➤ Subscribe 2015-12-18

Supplementary Protection Certificates for Salix Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0186405 SPC/GB00/021 United Kingdom ⤷  Sign Up PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
3347352 2290051-8 Sweden ⤷  Sign Up PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819
1856135 2090014-8 Sweden ⤷  Sign Up PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE OR SOLVATE OF FOSTAMATINIB OR THE PH ARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1912999 1490062-5 Sweden ⤷  Sign Up PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
0806968 SPC/GB07/011 United Kingdom ⤷  Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.